Navigation Links
United Therapeutics Announces Additional $100 Million Share Repurchase Program
Date:6/27/2012

SILVER SPRING, Md., June 27, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced  that its Board of Directors authorized the repurchase of up to an additional $100 million of the company's common stock.  This program will become effective on July 31, 2012, and will remain open for up to one year.  Purchases may be made in the open market or in privately negotiated transactions from time to time as determined by United Therapeutics' management and in accordance with the requirements of the U.S. Securities and Exchange Commission.

The company also announced that it had recently completed its previously-announced $300 million repurchase program by purchasing 2,045,192 shares of common stock for $88 million during the second quarter of 2012.

"I am pleased that we have completed our $300 million share repurchase program, and that our board has authorized an additional $100 million in share repurchases," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer.  "Given our current share price and the continued strong performance of our core business, we continue to believe that repurchases represent an appropriate use of our capital and an opportunity to return value to our shareholders."

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding future repurchases of shares of our co
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
2. Strategic Analysis of the Collagen Peptide Market in the United States
3. Animal Husbandry Equipment Market in United States: Business Report 2011
4. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
5. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
6. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
7. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
8. Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
9. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
10. Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
11. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... PARIS , July 30, 2015 ... leader, reports results for the second quarter of ... the group,s results and its performance in different ... transcript:  http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire ... - Q2 results - Performance drivers ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... manufacturer and supplier, announces the launch of their 2nd generation cell therapy POD® ... current miniPOD CT, but it also represents a new POD® design. , ...
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2
... Corporation (OTC Bulletin Board: MFLU) announced today that the ... Monday, November 2, 2009, after the closing of the ... ) , Michael C. Ferrara, President and Chief ... Finance and Chief Accounting Officer, will host a conference ...
... -- In response to requests from clients, Schulman ... , The Schulman Canadian Board,s first official meeting is ... are conducted in both the U.S. and Canada, Canadian and ... to maintain consistency. , "Our clients have asked us to ...
... The Board of Directors of Biomoda, Inc. (OTC Bulletin ... cancer detection medical diagnostics company, has elected Maria Zannes ... the Biomoda Board May 1, 2008. , "Maria,s extraordinary ... perfect individual to safeguard our commitment to good corporate ...
Cached Biology Technology:Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 2Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 3Schulman Associates IRB Establishes an Institutional Review Board in Canada 2Biomoda Board of Directors Names New Corporate Secretary 2
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... scleroderma has slowed Tracy Zinn but it has not stopped ... accommodating employer, Zinn is now in her 13th year as ... But, many with the incapacitating disease are not as fortunate. ... people with systemic scleroderma, also known as systemic sclerosis, is ...
... 2011 DigitalPersona, Inc. , a global provider ... Pizza Hut™ franchisee Rage, Inc. has rolled out ... locations throughout the east coast in South Carolina, North ... By deploying fingerprint biometrics as a part of their ...
... 2001--Eating nuts every day could help control Type 2 ... from St. Michael,s Hospital and the University of Toronto. ... Diabetes Care , a team of researchers led ... Nutritional Sciences; St. Michael,s Hospital Risk Factor Modification Centre) ...
Cached Biology News:Scleroderma study identifies roadblocks to employment 2Scleroderma study identifies roadblocks to employment 3Pizza Hut Franchisee Saves Dough by Slicing Payroll Fraud and Leavening Store Revenue with Digital Persona Fingerprint Biometrics 2A 'nutty' solution to type 2 diabetes management 2
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Hepatocyte Differentiation Environment...
Biology Products: